Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 119 clinical trials
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib when given in combination with pembrolizumab in up to 106 participants with previously treated, advanced adenocarcinoma of the lung. The study will enroll three cohorts of participants with previously treated, advanced …

lung carcinoma
treatment regimen
lung cancer
platelet count
EGFR
  • 340 views
  • 29 Jan, 2022
  • 12 locations
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03)  

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progression free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

  • 119 views
  • 18 Aug, 2022
  • 5 locations
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO (MOIO)

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as …

kinase inhibitor
tyrosine
breast cancer
lung cancer
cytotoxic t-lymphocyte antigen 4
  • 0 views
  • 09 Jul, 2022
  • 19 locations
First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled …

monoclonal antibodies
programmed cell death 1 ligand 1
measurable disease
cancer
lung cancer
  • 137 views
  • 19 Apr, 2022
  • 81 locations
DBT for Metastatic Lung Cancer (DBT-MLC)

Metastatic lung cancer patients experience significantly greater psychological distress (i.e., depression, anxiety) compared to other cancers. Psychological distress is as a prognostic indicator

  • 0 views
  • 09 Jul, 2022
  • 1 location
Piloting Pathways With Lung Cancer Patients

The purpose of this research is to determine the feasibility of a new supportive intervention, called Pathways, for patients with advanced stage and metastatic lung cancer.

cancer treatment
cancer
lung cancer
  • 0 views
  • 22 Mar, 2022
  • 1 location
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer

The goal of the study is to identify the maximum tolerated dose of endobronchial ultrasound-guided transbronchial injection (EBUS-TBNI) of cisplatin for Stage IV lung cancer.

cancer
lung cancer
  • 0 views
  • 05 Jun, 2022
  • 1 location
Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer (SUPPRESS-NSCLC)

A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, …

  • 0 views
  • 10 May, 2022
  • 1 location
Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

This study aims to evaluate the efficacy and safety of DS-1062a in participants with metastatic, unresectable NSCLC having progressed on one, but not more than three previous standard therapies. Moreover, the immune effects, the predictors of resistance and response to treatment, the effect of the chemotherapy on deoxyribonucleic acid (DNA) …

  • 0 views
  • 02 Jul, 2021
  • 1 location
Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer (LIBELULE)

hypothesize that using systematic LB in patients with clinical suspicion of metastatic lung cancer may reduce time-to-treatment initiation and avoid tissue rebiopsy. Investigators performed a

cancer treatment
ROS1
cancer
lung cancer
KRAS
  • 1 views
  • 09 Feb, 2022
  • 15 locations